Navigation Links
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Date:11/14/2007

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, and the expected progress and timing of the liver cancer therapeutic program constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
11. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... Hayden-McNeil is pleased to ... course materials for smaller courses. This program is specifically ... 200 students. , “I’m very excited about offering ... education instructors,” said Jeff McCarthy, Hayden-McNeil president. “By working ... our part to make education both more effective and ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... create an independent analysis designed to reflect the ... over time. This model will be used to ... for CHF, could have on those groups of ...
(Date:5/5/2015)... Franz Inc ., the leading supplier of Semantic ... AllegroGraph, has been named a Champion by Bloor Research in ... AllegroGraph is a high performance Semantic Graph Database that enables ... skyrocketing in popularity and have grown by 400% in the ... by DB-Engines. , “We are excited that Graph and ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... sonar sends out sound waves to explore the hidden ... scanning tunnelling microscopes to investigate the well-hidden properties of ... Halle and Jlich now report in the high-impact journal ... surfaces visible in this manner. Fermi surfaces determine the ...
... provides a new, fast-acting(1) combination treatment option for ... Feb. 27 AstraZeneca (NYSE: ... Food and Drug Administration (FDA) has approved SYMBICORT ... daily maintenance treatment of airflow obstruction in patients ...
... Spectrometry System Intended for Veterinary Drug Residue Analysis ... Waters Corporation (NYSE: WAT ) announced ... Agricultural Research Service has purchased a Waters(R) ACQUITY(R) ... methods for screening poultry and beef for trace ...
Cached Biology Technology:Latest issue of Science: Nano-sonar uses electrons to measure under the surface 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6USDA Boosts Food Safety Research with Purchase of Waters ACQUITY TQD System 2USDA Boosts Food Safety Research with Purchase of Waters ACQUITY TQD System 3
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... the autistic brain has fewer neurons in an area related ... published in the July 19 issue of The Journal ... linking autism to an abnormality of the amygdala, especially the ... the brain responsible for higher cognitive functions. , ...
... Mayo Clinic researchers have found that years after ... declines greater than expected in their elderly counterparts, ... may be commensurate with normal aging. , "Other ... aggressive condition later in life, but we've actually ...
... American and South African scientists working at the epicenter ... how the human immunodeficiency virus (HIV) "exhausts" killer T ... found that HIV can simply "turn off" fully functional ... cells. In test tube studies, however, the scientists showed ...
Cached Biology News:Autistic brain has fewer neurons for processing emotion 2Survivors of childhood polio do well decades later as they age 2A new tool against brain disease 2A new tool against brain disease 3A new tool against brain disease 4
... UNOsphere ion exchange media ... with high binding capacity. ... is a strong cation ... size of 120 micrometers. ...
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,487-9) or ... ID clarifier: centre neck 100 mm, ...
Packaging: 6 bottles for 1 l ready-to-use-solution ID clarifier: ready-to-use solution ...
... Bio-Beads S-X media are neutral, ... size exclusion chromatography of lipophilic ... require organic eluents. The beads ... xylene, carbon tetrachloride, dimethylformamide, ketones, ...
Biology Products: